SEC Form 4
TriSalus Life Sciences, Inc. (TLSI) insider trading
In the 12 months to Oct 26, 2026, 6 TLSI insiders reported open-market purchases of $3.6M across 10 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $3.6M
- 10 filings
Who traded TLSI, and when
- Purchase
TLSI daily close from Oct 27, 2025 to Oct 26, 2026, between $2.52 and $7.50, last $3.64. 0 sale and 10 purchase filings by 6 insiders, marked at their filing dates. Michael P. Stansky, Director: bought $3.0M across 2 filings, first filed Feb 23, 2026, last May 18, 2026. Mary T. Szela, CEO and President: bought $227.8K across 2 filings, first filed Feb 23, 2026, last May 18, 2026. Mats Wahlstrom, Director: bought $151.8K across 1 filing, first filed May 18, 2026, last May 18, 2026. William Valle, Director: bought $125.0K across 1 filing, first filed Feb 23, 2026, last Feb 23, 2026. Gary B. Gordon, Director: bought $64.6K across 2 filings, first filed Feb 23, 2026, last May 18, 2026. David Patience, Chief Financial Officer: bought $32.2K across 2 filings, first filed Feb 23, 2026, last May 18, 2026.
Largest mark · tap a row for others
Michael P. Stansky · Director
Purchase $1,525,000
610,000 shares at $2.50 avg
Filed May 18, 2026 · traded May 15
Close on filing date $3.03
Michael P. Stansky · Director
Director
$3.0M boughtMary T. Szela · CEO and President
CEO and President
$227.8K boughtMats Wahlstrom · Director
Director
$151.8K boughtWilliam Valle · Director
Director
$125.0K boughtGary B. Gordon · Director
Director
$64.6K boughtDavid Patience · Chief Financial Officer
Chief Financial Officer
$32.2K boughtOpen-market trades
10 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Michael P. Stansky | Director | — | $3.0M | 2 | — | |
| Mary T. Szela | CEO and President | — | $227.8K | 2 | — | |
| Mats Wahlstrom | Director | — | $151.8K | 1 | — | |
| William Valle | Director | — | $125.0K | 1 | — | |
| Gary B. Gordon | Director | — | $64.6K | 2 | — | |
| David Patience | Chief Financial Officer | — | $32.2K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Gary B. Gordon Director | Purchase | 10,000 | $2.46 | $24.6K | 72,510 | |
traded | David Patience Chief Financial Officer | Purchase | 7,100 | $2.43 | $17.3K | 275,757 | |
traded | Mary T. Szela CEO and President | Purchase | 39,682 | $2.59 | $102.8K | 1,065,215 | |
traded | Michael P. Stansky Director | Purchase | 610,000 | $2.50 | $1.5M | Multiple accounts | |
traded | Mats Wahlstrom Director | Purchase | 60,000 | $2.53 | $151.8K | 147,555 | |
traded | Michael P. Stansky Director | Purchase | 361,098 | $4.10 | $1.5M | Multiple accounts | |
traded | Mary T. Szela CEO and President | Purchase | 30,487 | $4.10 | $125.0K | 773,289 | |
traded | William Valle Director | Purchase | 30,487 | $4.10 | $125.0K | 30,487 | |
traded | Gary B. Gordon Director | Purchase | 9,756 | $4.10 | $40.0K | 9,756 | |
traded | David Patience Chief Financial Officer | Purchase | 3,657 | $4.10 | $15.0K | 268,657 |
GET /stocks/filings/vX/form-4?tickers=TLSI&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"TLSI",
"TLSIW"
],
"issuer_cik": "0001826667",
"owner_cik": "0001424204",
"accession_number": "0001628280-26-035995",
"form_type": "4",
"filing_date": "2026-05-18",
"period_of_report": "2026-05-15",
"issuer_name": "TriSalus Life Sciences, Inc.",
"issuer_trading_symbol": "TLSI",
"owner_name": "Stansky Michael P",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-05-15",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 200000,
"transaction_price_per_share": 2.5,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 399698,
"transaction_value": 500000,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By Skyview Investments LLC",
"footnotes": [
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."
},
{
"id": "F3",
"description": "The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member."
}
]
},
{
"tickers": [
"TLSI",
"TLSIW"
],
"issuer_cik": "0001826667",
"owner_cik": "0001811354",
"accession_number": "0001628280-26-035991",
"form_type": "4",
"filing_date": "2026-05-18",
"period_of_report": "2026-05-15",
"issuer_name": "TriSalus Life Sciences, Inc.",
"issuer_trading_symbol": "TLSI",
"owner_name": "Gordon Gary B.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-05-15",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 10000,
"transaction_price_per_share": 2.46,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 72510,
"transaction_value": 24600,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 44 records
- Tax withholding2 records
- Tax withholding (sold to cover)18 records
- Grants and awards22 records
- Other2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has TriSalus Life Sciences, Inc.'s CEO sold stock?
No. Mary T. Szela (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is TLSI’s insider data?
These are TLSI Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track TLSI insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for TLSI every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.